Insight Molecular Diagnostics (IMDX) Sidoti Micro-Cap Virtual Conference summary

Company evolution and strategic focus

• Transitioned from a lab-based to a product-focused business, emphasizing democratization of technology and partnerships over building proprietary commercial channels.

• Reduced average cash burn to under $5 million per quarter over the past year, down from $10 million previously.

• Successfully shipped first products to beta customers in June and secured a partnership and investment from Bio-Rad.

• Delivered on promises to lower burn, create a product, and find a partner, leading to renewed investor support and a streamlined capital structure.

• CEO's background includes business development and leading the transition from lab to product company after joining in December 2022.

Product innovation and market opportunity

• Launched GraftAssure, a Research Use Only (RUO) kit that measures donor-derived cell-free DNA to monitor transplant rejection.

• Technology enables local transplant centers to perform testing, improving turnaround time and patient management compared to centralized labs.

• RUO product serves as a land strategy, building relationships and familiarity ahead of FDA-approved IVD product launch.

• Product leverages proprietary IP acquired through a German acquisition, offering ease of use and rapid results via PCR technology.

• Market is highly concentrated, with about 100 centers handling 80% of U.S. transplant volume, allowing for efficient sales efforts.

Financial outlook and business model

• RUO product is not a major revenue driver but establishes an installed base for future high-margin, recurring revenue from IVD product.

• Similar tests are reimbursed at over $2,000, with manufacturing costs in the tens of dollars, supporting strong gross margins.

• Pricing for the IVD product is expected in the mid-hundreds per test, with favorable unit economics for both company and users.

• Break-even revenue depends on a core cash burn of $5–6 million per quarter and software-like gross margins.

• April capital raise was completed at market with no warrants, resulting in a clean balance sheet with only common stock and no debt.